These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 29335738)

  • 21. Drug-Drug Interactions in Patients Co-infected With HCV and HIV--Reply.
    Osinusi A; Townsend K; Kottilil S
    JAMA; 2015 Jul; 314(2):186-7. PubMed ID: 26172900
    [No Abstract]   [Full Text] [Related]  

  • 22. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient.
    Taibi C; Tempestilli M; D'Avolio A; Garbuglia AR; De Nicolò A; Montalbano M; D'Offizi G
    J Clin Pharm Ther; 2017 Oct; 42(5):621-623. PubMed ID: 28474408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment.
    Gentile I; Borgia G
    Evid Based Med; 2014 Dec; 19(6):223-4. PubMed ID: 25028605
    [No Abstract]   [Full Text] [Related]  

  • 25. Cure with ledipasvir/sofosbuvir for chronic hepatitis C virus in an individual with gastric bypass.
    Johnson SW; Teachey AL; Valanejad SM; Griffin SM; Weber SF
    J Clin Pharm Ther; 2017 Oct; 42(5):624-626. PubMed ID: 28474386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EFFECTIVE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTIONS WITH DIRECT ACTING ANTIVIRALS IN PRISONS SYSTEM.
    Vashakidze E; Imnadze T; Mikadze I
    Georgian Med News; 2018 Jan; (274):112-116. PubMed ID: 29461238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viral hepatitis: new hepatitis C therapies-a medical pick and mix.
    Ray K
    Nat Rev Gastroenterol Hepatol; 2014 Jun; 11(6):329. PubMed ID: 24776807
    [No Abstract]   [Full Text] [Related]  

  • 28. [LDV/SOF successful in general practice test].
    Bischoff M
    MMW Fortschr Med; 2016 Jun; 158 Suppl 1():62. PubMed ID: 27259909
    [No Abstract]   [Full Text] [Related]  

  • 29. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
    Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
    J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Sofosbuvir/ledipasvir is also effective in routine general practice].
    Warpakowski A
    MMW Fortschr Med; 2016 Apr; 158 Spec No 1():65. PubMed ID: 27090681
    [No Abstract]   [Full Text] [Related]  

  • 31. Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients.
    Peter J; Nelson DR
    Liver Int; 2015 Jan; 35 Suppl 1():65-70. PubMed ID: 25529089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two Antiviral Drugs Approved For Adolescents With HCV.
    Aschenbrenner DS
    Am J Nurs; 2017 Aug; 117(8):22. PubMed ID: 28749879
    [No Abstract]   [Full Text] [Related]  

  • 33. Sovaldi dilemma likely to get worse.
    Carroll J
    Manag Care; 2014 Sep; 23(9):9, 12. PubMed ID: 25282860
    [No Abstract]   [Full Text] [Related]  

  • 34. Successful evolution of morphea after hepatitis C virus eradication with direct-acting antiviral agent treatment.
    Guerra Romero AR; Pérez Figueras M; Alonso López S
    Rev Esp Enferm Dig; 2019 Dec; 111(12):973. PubMed ID: 31696725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Moser S; Kozbial K; Laferl H; Schütz A; Reiberger T; Schwabl P; Gutic E; Schwanke C; Schubert R; Luhn J; Lang T; Schleicher M; Steindl-Munda P; Haltmayer H; Ferenci P; Gschwantler M
    Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):291-295. PubMed ID: 29120906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment.
    Okubo T; Atsukawa M; Tsubota A; Toyoda H; Shimada N; Abe H; Kato K; Hayama K; Arai T; Nakagawa-Iwashita A; Itokawa N; Kondo C; Kawamoto C; Iio E; Tanaka Y; Kumada T; Iwakiri K
    Hepatol Int; 2018 Mar; 12(2):133-142. PubMed ID: 29600429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Harvoni (ledipasvir and sofosbuvir) for hepatitis C.
    Mullins C; Gibson W; Klibanov OM
    Nurse Pract; 2015 Nov; 40(11):22-6. PubMed ID: 26474199
    [No Abstract]   [Full Text] [Related]  

  • 38. Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV.
    Tadokoro T; Morishita A; Fujita K; Oura K; Sakamoto T; Nomura T; Tani J; Yoneyama H; Masaki T
    Intern Med; 2018 Apr; 57(8):1101-1104. PubMed ID: 29279506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kidney transplant recipients with hepatitis C virus experienced 100% sustained virologic response at 12 weeks when treated with sofosbuvir-ledipasvir.
    Sise ME
    Hepatology; 2017 Oct; 66(4):1335-1337. PubMed ID: 28650558
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
    Alqahtani SA; Afdhal N; Zeuzem S; Gordon SC; Mangia A; Kwo P; Fried M; Yang JC; Ding X; Pang PS; McHutchison JG; Pound D; Reddy KR; Marcellin P; Kowdley KV; Sulkowski M
    Hepatology; 2015 Jul; 62(1):25-30. PubMed ID: 25963890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.